tbuckley/cabot-search huggingface dataset:
ACTR-26. CARBOPLATIN-BASED CHEMOTHERAPY AFTER TEMOZOLOMIDE FAILURE IN HIGH-GRADE GLIOMAS. VOLUMETRIC ANALYSES
Authors: Satoshi Nakasu, Nakamasa Hayashi, Koichi Mitsuya, Hirofumi Nioka, Ken-ichi Matsumura, Yoko Nakasu
Journal: Neuro-Oncology (2016)

Treatment of recurrent anaplastic gliomas (AGs) and glioblastomas (GBMs) remains a challenge in neuro-oncology. Many regimens have been tried, while only marginal responses were reported. We evaluated responses to carboplatin-based chemotherapy (CB) using precise volumetric measurement. METHOD: We retrospectively found 16 patients treated with CB after temozolomide (TMZ) failure (6GBMs, 10AGs). Carboplatin and etoposide were administered to them, with additional ifosphamide to five. None of them were treated with bevacizumab before and during CB. We measured each volume of the tumors in MRI T1Gd images using an imaging software. Tumor volume doubling time (Td) was calculated both in the period of CB and TMZ treatment. Overall, this regimen provided 4 partial response (PR), 6 stable disease (SD), and 6 progressive disease (PD) in MacDonald criteria. In patients with GBM, responses were generally poor with only 1 PR and 1SD. The median PFS was 8.4 weeks. In patients with AG, there were 3 PR, 5 SD and 2 PD. The median PFS was 32.5 weeks. Volumetric analyses showed the median Tds were 73.2 days in AGs and 13.3 days in GBMs during the last TMZ therapy. Two GBMs and 6 AGs decreased their volume more than 10% after CB. Three GBMs and 2 AGs prolonged Td more than twice. Six patients experienced grade 3 or 4 bone marrow toxicity. CB showed moderate efficacy in patients with AG. Although CB produced poor responses in patients with GBM by MacDonald criteria, it decreased a volume or delayed growth in five of the six by volumetric analysis. These results suggest that CB may be useful for recurrent AGs. It may also have a role for small recurrent GBMs inducing delay of their growth. Volumetric analysis is time-consuming but useful for accurate response assessment in a small group.
Daily C - Reactive Protein (CRP) Levels Allow Early Identification of Patients with Severe Complications after Melphalan (MEL) and Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM).
Authors: Elias J. Anaissie, Monica L. Grazziutti, Athanasios Fassas, Li Dong, Miceli H. Miceli, Frits Van Rhee, Klaus A. Hollmig, Giampaolo Talamo, Guido J. Tricot, Bart Barlogie
Journal: Blood (2004)
Weight control strategies in breast cancer patients: A systematic review.
Authors: Nathalie LeVasseur, Mark J. Clemons, Sasha Mazzarello, Lisa Vandermeer, Lee Jones, Anil Abraham Joy, Stephanie Smith, Brian Hutton, John Frederick Hilton
Journal: Journal of Clinical Oncology (2016)

179 Background: Obesity remains an underestimated contributor to global cancer incidence and cancer-related mortality. Accumulating evidence suggests excessive energy intake and suboptimal levels of physical activity may be important after the diagnosis of cancer and may influence recurrence and overall survival(OS). Objective: Conduct a systematic review to evaluate data from randomized trials of weight control strategies used in breast cancer patients. Methods: A systematic search of Medline, Embase and the Cochrane Register of Controlled Trials through April 2015 was performed. Randomized trials of weight management strategies in breast cancer patients were sought. Outcomes studied included; change in weight, BMI and waist circumference, disease-free survival, recurrence-free survival and OS survival. Random effects meta-analyses were planned provided that included studies were considered to be clinically and methodologically homogenous. Results: Of 2876 abstracts, 312 were retained for review of the full texts. Overall 43 publications describing 40 studies met inclusion criteria. Of 12,801 enrolled patients, 11,597 had breast cancer. Fifteen studies consisted of dietary interventions, 17 consisted of exercise interventions and 8 consisted of both dietary and exercise interventions. Endpoints included: changes in weight (32 studies, 7,861 pts), BMI (12 studies, 1,886 pts), waist circumference (10 studies, 702 pts), recurrence-free survival (4 studies, 6105 pts) and overall survival (2 studies, 3,330 pts). Network meta-analyses of available data are in progress. Study results suggest that weight control strategies including dietary and exercise interventions were effective at reducing weight, BMI and waist circumference. Two large studies showed statistically significant recurrence-free survival benefits with weight control strategies and one showed OS benefit with an exercise intervention. Conclusions: Data from included trials suggest benefits of weight control strategies to decrease weight, BMI and waist circumference. Few trials have been designed to detect PFS or OS benefits. Larger trials are warranted to better define the role of weight control strategies in the management of breast cancer patients.
Assessing the impact of an online survivorship program.
Authors: Helayne Waldman, Shani Fox
Journal: Journal of Clinical Oncology (2016)

e285 Background: In the report From Cancer Patient to Cancer Survivor: Lost in Transition (2006), the Institute of Medicine identified follow-up of cancer survivors as a missing link in cancer care and made recommendations to the medical establishment to fill that gap. So far, studies of recommendation effectiveness have revolved around survivorship care plan implementation. However, a 2013 study indicated that use of SCPs is still more the exception than the rule. Methods: We have created a unique online program that is intended to address two key mandates of the IOM report: 1) Educationfor theprevention of recurrent and new cancers, and 2) Self-carestrategiesto help deal with consequences of cancer and its treatment i.e. lymphedema, fatigue; [and] psychological distress. Dr. Helayne Waldman and Dr. Shani Foxhave fashioned an online, real time, 12 week education and support program for cancer survivors, the first of its type in the U.S. The focus of the content is on maintaining wellness after treatment and includes topics such as physical activity, dietary guidelines, inflammation control and stress management. The program also contains a coaching component, where participants track their activities and share information via live discussion and interactive blogs. Results: We have established a framework for gathering, analyzing and reporting our data. Our target sample size is 40-50 participants. At the program’s outset we will administer a 20 question self-assessment to test participants’ knowledge of self-care practices and attitudes about their current state of wellness. At the program’s end in December we'll readminister in order to measure the change in both knowledge and attitude. We’ll then conduct an analysis of the data, and will report our findings at the ASCO meeting in January. Conclusions: We believe that education and support for survivors is critical to their physical and emotional well-being. Unfortunately, there is currently no program available to do this in a live, interactive format from the comfort of one’s home. We believe PCPs, hospital support groups and other non-profits will find this type of program to be an invaluable resource in serving to educate and manage the concerns of cancer survivors and to move closer to realizing the promise of the IOM report.
Circadian function of patients with advanced non-small cell lung cancer
Authors: R. D. Levin, J. F. Grutsch, W. J. M. Hrushesky, J. Quiton, K. Quinn, M. Daehler, C. G. Lis
Journal: Journal of Clinical Oncology (2005)

7291 Background: Preclinical data shows that abolishing circadian function accelerates tumor progression and shortens survival, while restoring normal circadian function enhances the survival benefits of chemotherapy. A significant fraction of patients with advanced cancer express the symptoms of disrupted circadian function, such as poor sleep quality and fatigue. There is little data in the literature on circadian function of cancer patients. Consequently, we measured the prevalence of symptoms associated with a disrupted circadian rhythm in advanced non-small cell lung cancer. Methods: Prior to initiation of therapy, actigraphy bracelets were worn on the non-dominant wrist for at least three days. The Pittsburgh Sleep Quality Index (PSQI), assessed sleep quality; European Organization for Research and Treatment for Cancer Care (EORTC) and the Ferrans and Powers Quality of Life Index (QLI) assessed quality of life and fatigue levels. Results: At the time of analysis there were 21 male and 12 female patients enrolled in the study. 20 had metastatic disease while 13 were stage III. 18 had prior treatment while 15 were newly diagnosed. The mean PSQI score was 10.6, a score routinely recorded in insomniacs. QLI domain scores were one to two standard deviations lower and EORTC domain scores were one standard deviation lower than the general population norms with low scores indicating worse QoL. The mean EORTC fatigue item score of 53 was much higher than that in normal population (28.8), higher the score, worse the fatigue. The wrist actigraphs recorded that patients slept 148.5 minutes more during the putative wake span and 113.1 minutes less during the putative sleep span than population controls. Conclusions: Patients with advanced non-small cell lung cancer have significantly disturbed circadian rhythms - experience poor sleep quality, high levels of fatigue, and an overall poor quality of life. The interesting question is whether restoring the patients’ circadian function also improves sleep quality, reduces fatigue levels, and improves QoL. This issue is currently being investigated at our center in a randomized clinical trial evaluating the chronotherapeutic role of melatonin in the treatment of stage III and IV non-small cell lung cancer. No significant financial relationships to disclose.
Erratum: A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea (Annals of Internal Medicine (2005) 142 (805-812))
Authors: Herbert L Dupont, Zhi-Dong Jiang, P. C. Okhuysen, Charles D Ericsson, F. J. De La Cabada, Shi Ke
Journal: Annals of Internal Medicine (2005)
Occult disease detection in ovarian cancer based on anatomic location.
Authors: P. E. Rosenstiel, S. Cohen, P. R. Dottino
Journal: Journal of Clinical Oncology (2011)

e15553 Background: Second-look surgery for ovarian cancer can detect microscopic disease in the setting of clinical remission. There is a paucity of data, however, assessing microscopic disease based on anatomic location. We sought to determine the detection rate of microscopic disease based on anatomic location among a cohort of patients who underwent second-look surgery. Methods: A retrospective analysis of 47 second-look surgery patients from 1992 to 2010 was performed. Mean age was 55 years with an average interval of 249 days after primary surgery. All cases were epithelial histology type, 79% were Grade 3, and 66% were Stage IIIC or greater. Surgical pathology reports were used to define the sensitivity, negative predictive value, and rate of disease detection at different biopsy sites and cytology. Results: Among 47 patients, 27 (57%) were negative for disease, 2 (4.3%) were grossly positive, and 18 (38%) were microscopically positive. Overall, a mean of 31.6 biopsies were taken per patient at surgery. 12/18 microscopically positive patients had disease detected by biopsy and 13/17 had disease detected by cytology. The sensitivity and negative predictive value was 66.7% and 81.3% for biopsies collected and 76.5% and 85.2% for cytology. At the specimen level 5.7% (31/541) of all biopsies were positive. Among the biopsies, visually suspicious lesions (nodules, lesions or cysts) were positive in 3/7 positive patients and 17.2% (5/29) specimens. Random biopsies were positive in 11/18 positive patients and in 5.1% (26/512) specimens. The four most sampled anatomic sites were the pelvic sidewalls, abdominal wall, abdomino-pelvic adhesions, and the pelvic gutters accounting for 77.6% (420/541) of all biopsies in positive patients. Conclusions: This study assessed the ability of second-look surgery to detect microscopic disease through sampling of various anatomic sites. The sensitivity and negative predictive value of cytology exceeded collective biopsy sampling (Table). Based on our data, the estimated number of random biopsies needed to achieve 95% and 99% sensitivity are 58 and 89 respectively. Persistent disease No evidence of disease Biopsy positive 12 0 Biopsy negative 6 26 Cytology positive 13 0 Cytology negative 4 23
How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial
Authors: P. Lavaud, G. Gravis, C. Legoupil, S. Foulon, F. Joly, S. Oudard, F. Priou, M. Soulié, L. Mourey, I. Latorzeff, R. Delva, I. Krakowski, B. Laguerre, C. Theodore, J.-M. Ferrero, P. Beuzeboc, M. Habibian, J.M. Boher, G. Tergemina-Clain, K. Fizazi
Journal: Annals of Oncology (2016)
Effects of Anonna muricata L. (soursop) seeds oil improves in model in vivo and in vitro of type 1 diabetes mellitus
Authors: Laise Cedraz Pinto, Ana Tereza Cerqueira-lima, Samara dos Santos Suzart, Raiane Souza, Bruna Tosta, Hugo Bernardino Ferreira Silva, Anaque Oliveira Pires, Gerson Queiroz, Raimon RIOS Silva, Tatiane Teixeira, Keina Maciele Dourado, Veturia Oliveira Costa, Vanda Baqueiro, Caroline Oliveira de Souza, Janice Izabel Druzian, Karina Carla de Paula Medeiros, Cresio de Aragão Dantas Alves, Mariangela Vieira Lopes, Camila Alexandrina Figueiredo
Journal: Journal of Allergy and Clinical Immunology (2017)
Cohort study evaluating the impact of a discharge letter (DL) compared with usual care on adherence to surveillance following treatment for stage II/III colorectal cancer (CRC).
Authors: Janine Marie Davies, Eugene Batuyong, Sasha M. Lupichuk, Robert Hilsden, Misha Eliasziw, Jacob C. Easaw
Journal: Journal of Clinical Oncology (2012)

620 Background: The 2005 ASCO guidelines recommend surveillance testing and frequencies following surgical +/− adjuvant therapy for stage II/III CRC. In Canada, many patients are discharged from their oncologist to their primary care physician (PCP) for ongoing surveillance. However, adherence to surveillance recommendations is low. This cohort study evaluated adherence to surveillance 1 year after treatment of stage II/III CRC prior to and following implementation of a DL. Methods: Cohort 1 (C1) patients were retrospectively identified from the Alberta Cancer Registry following adjuvant therapy (as applicable) at a tertiary cancer centre (07/2006 - 09/2007). Cohort 2 (C2) patients were prospectively identified from the Registry and clinic records following adjuvant therapy (as applicable), as those discharged from the centre (10/2007 - 4/2009); DL was sent to the patient and PCP recommending surveillance tests and dates. Clinical, laboratory, diagnostic imaging, and endoscopy data was collated. Adherence at 1 year follow-up was compared between cohorts using Kaplan-Meier time-to-event analyses. Results: C1 (n=218) was larger than C2 (n=114) despite the longer accrual time for C2. There were no differences between cohorts by age, sex, primary site of disease, stage, or adjuvant oxaliplatin use. During year 1 of follow-up, 11.8% and 11.4% recurred (local or metastatic) and 6.5% and 2.7% died (p=0.1) in C1 and C2 respectively. Comparing C1 with C2, 14.8% vs. 23.0% of patients had one CEA test within 3 months, 45.2% vs. 72.2% within 6 months, and 71.7% vs. 85.1% within 1 year (p&lt;0.001). Only 44.0% (C1) and 68.6% (C2) had 2 CEA tests within 1 year. Only 3.9% (C1) vs. 6.6% (C2) of patients had 4 CEA tests within the year following treatment as recommended. The rate of CT imaging was 32.3% (C1) and 56.1% (C2); endoscopy was 36.7% (C1) and 42.1% (C2). Conclusions: Implementation of a DL improved compliance with surveillance at 1 year of follow-up following discharge from a tertiary cancer centre, although optimal adherence remains low. However, adherence to CT imaging nearly doubled. Evaluation of compliance at 3 years of follow-up is ongoing.
RARE-16. A CASE REPORT OF AUTOGRAFT OLFACTORY STEM CELL TRANSPLANT FOR SPINAL CORD INJURY DEVELOPING INTO A PERSISTENT SPINAL MASS
Authors: Rodica Bernatowicz, Navin Sabharwal, Emily Bennett, Abdi Ghodsi, Andrew Healy, Edward Benzel, Glen Stevens
Journal: Neuro-Oncology (2016)

Patients that suffer spinal cord injury (SCI) often suffer detrimental loss of motor, sensory, or autonomic function. The central nervous system has limited regenerative potential and neuronal damage caused by SCI is often severe and even irreversible. To date, there is no established treatment for SCI. Stem cell transplantation has been the focus of ample research as a potential treatment for patients with SCI. Few and mainly experimental data exist on the use of stem cell transplant for SCI. The theory behind using stem cells to treat SCI is that pluripotent stem cells have the ability to differentiate and acquire characteristics of target tissues. However, the cells’ ability to self-renew carries the risk of uncontrolled cell growth and tumor formation. We report a case of olfactory mucosal stem cell transplantation for traumatic SCI at the level of C6-7. Three years after the transplant, the patient developed new neurological symptoms of arm weakness. MRI showed a multi-lobulated mass at the site of the stem cell transplant. The tumor was surgically removed and pathological analysis revealed mucosal cells within the mass suggesting that it had originated from the olfactory mucosal transplant. The patient had to undergo several resections due to regrowth of the mass and recurrent symptoms. To our knowledge this is only the third reported case of mass formation following stem cell transplant into central nervous system tissue. This case represents a disastrous complication of stem cell transplantation and highlights the need for additional clinical studies to validate the use of stem cell transplant for the treatment.
An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Carlo Gambacorti-Passerini, Dong-Wook Kim, Hagop M. Kantarjian, Tim H. Brummendorf, Irina Dyagil, Laimonas Griskevicius, Hemant Malhotra, Yeow-Tee Goh, Junyuan Wang, Karin Gogat, Jorge Cortes
Journal: Blood (2010)
231P Nomogram to predict prognosis in thoracic esophageal squamous cell carcinoma after neoadjuvant radiotherapy or chemoradiotherapy
Authors: W. Deng, Q. Wang, Z. Xiao, L. Tan, Z. Zhou, H. Zhang, D. Chen, Q. Feng, J. Liang, S. Gao, K. Sun, G. Cheng, X. Liu, D. Fang, Q. Xue, Y. Mao, D. Wang
Journal: Annals of Oncology (2016)
407P Pembrolizumab Expanded Access Program (EAP) in Taiwan for patients with progressive advanced melanoma after prior ipilimumab treatment
Authors: C.-K. Yang, J.-H. Liu, C.-C. Lin, T.-C. Liu, P.-T. Cheng, C.-Y. Lin, H.-T. Hu, C.-R. Cao, W.-T. Huang, L.-P. Chen, W.-C. Chang
Journal: Annals of Oncology (2016)
Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes.
Authors: Koen van Besien, Justin Kline, Lucy A Godley, Richard A. Larson, Vu H. Nguyen, Olatoyosi Odenike, Elizabeth Shima Rich, Wendy Stock, Amittha Wickrema, Scott Allen, Paula del Cerro, Sarah Horowitz, Lisa Pape, Linda Schroeder, Andrew Artz
Journal: Blood (2009)
Second Mitochondria-Derived Activator of Caspases Mimetic Compounds (Smac) Enhance Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) Pro-Apoptotic Effect On Human Myeloid Leukemia Cell Lines.
Authors: Federica Servida, Cinzia Scavullo, Daniele Lecis, Pierfausto Seneci, Carmelo Drago, Carmelo CarloStella, Leonardo Manzoni, Giorgio Lambertenghi Deliliers, Domenico Delia, Francesco Onida
Journal: Blood (2009)
Differential Dose Dependent Effects of Recombinant FVIIa and Enhanced Activity Analogue (NN1731) on Thrombin Generation, Platelet Function and Clot Structure in Blood from Normal Volunteers and Patients with Factor VIII Deficiency with or without Factor VIII Inhibitor Antibodies.
Authors: Donald F. Brophy, Erika J. Martin, Melinda Nolte, Jan G. Kuhn, Sashidhar N. Reddy, Mirella Ezban, Marcus E. Carr
Journal: Blood (2005)
A multicenter phase II study of preoperative concurrent chemoradiotherapy with S-1 plus irinotecan for locally advanced rectal cancer: SAMRAI-2
Authors: M. Noda, T. Sato, K. Hayakawa, N. Tomita, N. Kamikonnya, S. Matoba, A. Uki, H. Baba, N. Oya, H. Hasegawa, N. Shigematu, K. Hida, T. Furuhata, T. Naitou, M. Shimada, K. Otuka, Y. Higuchi, Y. Sakai, M. Takeuchi, M. Watanabe
Journal: Annals of Oncology (2016)
Stem cell treatment? Please answer these simple questions first
Authors: Maarten H Moen, Haiko IMFL Pas
Journal: British Journal of Sports Medicine (2017)

Raphael Nadal had stem cells injected for back complaints in 2014 and the New York Jet’s Chris Johnson (NFL) received them to augment knee surgery. Kim Kardashian used stem cells to get her face optimally ready for her marriage. When extremely famous people are treated with stem cells, less famous people (also known as the ordinary people) start wanting this kind of treatment as well.

Many stem cell clinics have emerged around the world in the past decade to provide patients with innovative, groundbreaking, regenerative therapy.1 2 Many haematological, neurological, hepatic and musculoskeletal conditions are being treated in these clinics. Stem cell treatment is often provided at the patient’s own expense for thousands of dollars.

Theoretically, stem cell treatment could be a very potent way of treating and possibly curing a huge spectrum of diseases because of their regenerative and immunoregulatory potential. It therefore draws lots of attention from many care providers, athletes and patients worldwide and has led to a new word in the dictionary; stem …
A Multidisciplinary Care Management Program for Patients with Sickle Cell Syndromes Significantly Reduces Health Care Resource Utilization.
Authors: William S. Jonas, Matthew Hogan, Allan F. Platt, Melanie Jacob, JoAnn A. Beasley, Philip Lamson, Sheila Palmer, Hanna J. Khoury, James R. Eckman
Journal: Blood (2005)
The influence of clinical predictors on the results oftreatment with erlotinib in patients with advanced NSCLC
Authors: František Salajka, Miloš Pešek, J. Krejčí, J. Skřičková, P. Zatloukal, Leona Koubková, Y. Grygarová, Tomáš Pavlík
Journal: Journal of Thoracic Oncology (2009)
Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial
Authors: Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Raymonde Busch, Günther Fingerle-Rowson, Kirsten Fischer, Anna- Maria Fink, Ulrich Jäger, Sebastian Böttcher, Michael Kneba, Michael Wenger, Myriam Mendila, Michael Hallek, Hartmut Döhner
Journal: Blood (2008)
Satb1 Determines Hematopoietic Stem Cell Differentiation Toward the Lymphoid Lineages
Authors: Yusuke Satoh, Takafumi Yokota, Motonari Kondo, Paul W. Kincade, Taku Kouro, Ryuji Iida, Koichi Kokame, Toshiyuki Miyata, Takao Sudo, Hirokazu Tanaka, Itaru Matsumura, Kenji Oritani, Terumi Kohwi-Shigematsu, Yuzuru Kanakura
Journal: Blood (2011)
Cardiac mGluR1 metabotropic receptors in cardioprotection
Authors: Anne Vincent, Catherine Sportouch, Aurélie Covinhes, Christian Barrère, Laura Gallot, Viviana Delgado-Betancourt, Benoît Lattuca, Kamila Solecki, Prisca Boisguérin, Christophe Piot, Joël Nargeot, Stéphanie Barrère-Lemaire
Journal: Cardiovascular Research (2017)

In a previous study using a genome-wide microarray strategy, we identified metabotropic glutamate receptor 1 (mGluR1) as a putative cardioprotective candidate in ischaemic postconditioning (PostC). In the present study, we investigated the role of cardiac mGluR1 receptors during cardioprotection against myocardial ischaemia-reperfusion injury in the mouse myocardium.